# Table 4 Statistical distributions selected for each pharmacodynamic parameter

μ IPL a DU(4, 16)
σ IPL a DU(2, 8)
PMF a TRI(8, 12, 10)
k max ARS/DHA TRI(0.26, 0.47, 0.37)c PRR = 105.28; KZ = 38
ART TRI(0.12, 0.33, 0.22)c PRR = 102.9; KZ = 38
LF TRI(0.18, 0.54, 0.36)c PRR = 103; KZ = 22
MQ TRI(0.11, 0.46, 0.28)c PRR = 102.25; KZ = 22
PQ TRI(0.33, 0.65, 0.49)c PRR = 104.6; KZ = 24
γ ARS/DHA lnN(1.31, 0.65)
ART lnN(1.53, 0.31)
LF lnN (0.81, 0.58)
MQ lnN (0.97, 0.54)
PQ lnN (1.35, 0.66)
EC50 (ng/mL) ARS/DHA U(1.44, 532.05) a =$I C 50$ (adjusted)(ng/mL)b,d; b = 0.5×Cmax (ng/mL)b,d
ART U(4.38, 46.20)
LF U(1.75, 2331.60)
MQ U(20.48, 1087.22)
PQ U(11.56, 94.19)
1. ARS – artesunate, ART – artemether, DHA – dihydroartemisinin, LF – lumefantrine, MQ – mefloquine, PQ – piperaquine.
4. cThe mode of the triangular distribution for$k max$ (c) was calculated from the following expression:$k max = 1 / K Z × ln P R R + 1 / 48 × ln P M F$, where PRR is the parasite reduction ratio for the drug in the corresponding row; KZ is the length of the killing zone in hours for each drug in the corresponding row; PMF in this expression equals 10 parasites / 48 h. The lower /upper limit of the triangular distribution for$k max$ (a/b) is calculated by evaluating the latter expression$k max$ at a PRR decreased/increased by 50-fold (KZ remains unchanged).
5. d$I C 50$ (adjusted) =$I C 50$ × (100 – BM / 100) × (100 / 100 - HPPB) × HWB;